<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph" /><meta name="keywords" content="Thalidomide; Thalidomide; Thalidomide Celgene" /><meta name="IX" content="Thalidomide; Thalidomide Celgene" /><meta name="IXM" content="Thalidomide" /><title>THALIDOMIDE: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="201478.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="201478.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=201478.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4777.htm">8.2 Drugs affecting the immune response</a> &gt; <a href="4789.htm">8.2.4 Other immunomodulating drugs</a> &gt; <a href="200217.htm">Lenalidomide and thalidomide</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="200218.htm" title="Previous: LENALIDOMIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="201480.htm#_201480" title="Next: Thalidomide Celgene®">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a399032.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Thalidomide</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Biologic Response Modifiers 92:20</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/13316-v.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Thalidomide</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: T &gt; Interactions of Thalidomide</p></div></li></ul><ul><li><h3>British National Formulary (3)</h3></li><li><a href="3925.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">5.1.10 Antileprotic drugs</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 5 Infections &gt; 5.1 Antibacterial drugs</p></div></li><li><a href="200217.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lenalidomide and thalidomide</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs</p></div></li><li><a href="201480.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Thalidomide Celgene®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs &gt; Lenalidomide and thalidomide &gt; THALIDOMIDE</p></div></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/c-d1e1106708.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Thalidomide</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; T</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/13316-v.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Thalidomide</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/09255.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Thalidomide</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; T &gt; TH</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E14E3E0R0D1488.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Thalidomide</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; T</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_201478">THALIDOMIDE</h1><?highlighter on?><div id="pC" class="jN"><div class="cAF"><h2>Indications</h2> <p class="cAF">see <a title="monograph-family: Lenalidomide and thalidomide" href="200217.htm#_200217">notes above</a></p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">see <a title="monograph-family: Lenalidomide and thalidomide" href="200217.htm#_200217">notes above</a>; high
tumour burden—risk of <a title="BNF:target-block: Tunour lysis syndrome" href="100100.htm#_100100.8">tumour lysis syndrome</a>; monitor for
arterial or venous thromboembolism and
use caution with concomitant drugs that increase the risk of peripheral
neuropathy or thromboembolism—see also Thromboembolism,
below</p><div class="cAV"><h3>Thromboembolism</h3> <p class="cAX">Risk factors for thromboembolism
(such as smoking, hypertension, hyperlipidaemia) should be minimised.Thromboprophylaxis is recommended for at least the first 5 months
of treatment, especially in patients with additional thrombotic risk
factors. </p><p>Patients and their carers should be made aware
of the symptoms of thromboembolism and advised to report sudden breathlessness,
chest pain, or swelling of a limb</p></div><div class="cAV"><h3>Peripheral neuropathy</h3> <p class="cAX">Monitor patients
for signs and symptoms of peripheral neuropathy; patients and their carers should be advised to seek medical advice
if symptoms such as paraesthesia, abnormal coordination, or weakness
develop. Dose reduction, dose interruption, or treatment
discontinuation may be necessary—consult product literature. Patients with pre-existing peripheral neuropathy should not be treated
with thalidomide unless the potential clinical benefits outweigh the
risk</p></div></div><div class="cAF"><h2>Hepatic impairment</h2> <p class="cAF">caution in severe impairment— no information available</p></div><div class="cAF"><h2>Renal impairment</h2> <p class="cAF">caution in severe impairment— no information available</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF"><b>important teratogenic risk</b>; see
also <a title="BNF:target-block: Lenalidomide and thalidomide prgenancy notes" href="200217.htm#_201713">notes above</a></p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">avoid—present in milk in <i>animal</i> studies</p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF">vomiting, dry mouth, dyspepsia, constipation;
bradycardia, cardiac failure, deep vein thrombosis; dyspnoea, interstitial
lung disease, pulmonary embolism, peripheral oedema; asthenia, confusion,
depression, dizziness, drowsiness, peripheral neuropathy, dysaesthesia,
paraesthesia, syncope, tremor; pyrexia; pneumonia; anaemia, leucopenia,
neutropenia, lymphopenia, thrombocytopenia; skin reactions including
Stevens-Johnson syndrome; <i>also reported</i> toxic epidermal
necrolysis, intestinal obstruction, gastro-intestinal perforation,
hypothyroidism, sexual dysfunction, myocardial infarction, cerebrovascular
events</p></div><div class="cAF"><h2>Dose</h2> <p class="cR"><span class="cAK">adult</span> over 18 years, 200 mg
once daily at bedtime for 6-week cycle; max. 12 cycles</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="201480.htm#_201480" title="Thalidomide Celgene®">Thalidomide Celgene®</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="200218.htm">Previous: LENALIDOMIDE</a> | <a class="top" href="201478.htm#">Top</a> | <a accesskey="]" href="201480.htm#_201480" title="Thalidomide Celgene®">Next: Thalidomide Celgene®</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>